[Study of the molecular mechanisms controlling activity of protein p53 in the development of new strategies in cancer therapeutics].
P53 is 30. Even if the tumor suppressor functions of p53 have long been recognized, the cancer-killing activity of p53 has not yet been exploited selectively and efficiently in the clinic. Recent genetic studies in mice identified MDM2 and MDMX as key regulators of p53 and as such as specific chemotherapeutic targets for treatment of cancer. Specific MDM2 and MDMX antagonists are now being developed as tools to unleash p53 activity in various tumors.
Marine
Ch
Ch
Universiteit Gent, Laboratory for Cancer Biology.
D000818:Animals; D017209:Apoptosis; D002453:Cell Cycle; D018797:Cell Cycle Proteins; D005784:Gene Amplification; D016147:Genes, Tumor Suppressor; D016158:Genes, p53; D016678:Genome; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D009687:Nuclear Proteins / Q000235:genetics; D009857:Oncogenes; D011518:Proto-Oncogene Proteins / Q000235:genetics; D051736:Proto-Oncogene Proteins c-mdm2 / Q000235:genetics; D014158:Transcription, Genetic; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
D018797:Cell Cycle Proteins; C482775:MDM4 protein, human; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D016159:Tumor Suppressor Protein p53; D051736:Proto-Oncogene Proteins c-mdm2